Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.
von Eyben FE, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP. von Eyben FE, et al. Among authors: virgolini i. Oncotarget. 2019 Mar 29;10(25):2451-2461. doi: 10.18632/oncotarget.26789. eCollection 2019 Mar 29. Oncotarget. 2019. PMID: 31069008 Free PMC article.
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, Virgolini I. Maffey-Steffan J, et al. Among authors: virgolini i. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):695-712. doi: 10.1007/s00259-019-04583-2. Epub 2019 Nov 27. Eur J Nucl Med Mol Imaging. 2020. PMID: 31776632 Free PMC article.
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, Kulkarni HR, Zhang J, Gerke C, Fimmers R, Kratochwil C, Rathke H, Ilhan H, Maffey-Steffan J, Sathekge M, Kabasakal L, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I. Ahmadzadehfar H, et al. Among authors: virgolini i. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):113-122. doi: 10.1007/s00259-020-04797-9. Epub 2020 May 8. Eur J Nucl Med Mol Imaging. 2021. PMID: 32383093 Free PMC article.
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
Ahmadzadehfar H, Matern R, Baum RP, Seifert R, Kessel K, Bögemann M, Kratochwil C, Rathke H, Ilhan H, Svirydenka H, Sathekge M, Kabasakal L, Yordanova A, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I, Rahbar K. Ahmadzadehfar H, et al. Among authors: virgolini i. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4067-4076. doi: 10.1007/s00259-021-05383-3. Epub 2021 May 25. Eur J Nucl Med Mol Imaging. 2021. PMID: 34031719
177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
von Eyben FE, Kairemo K, Paller C, Hoffmann MA, Paganelli G, Virgolini I, Roviello G. von Eyben FE, et al. Among authors: virgolini i. Biomedicines. 2021 Aug 19;9(8):1042. doi: 10.3390/biomedicines9081042. Biomedicines. 2021. PMID: 34440246 Free PMC article. Review.
320 results